Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products geared towards addressing unmet needs and providing unique and meaningful advantages to patients with renal disease and their healthcare providers. Patients have been and continue to be at the center of our 16-year corporate history.
Type
Public
HQ
New York, US
Size (employees)
193 (est)+5%
Website
keryx.com
Keryx Biopharmaceuticals is headquartered in New York, US

Keryx Biopharmaceuticals Office Locations

Keryx Biopharmaceuticals has offices in New York and Boston
New York, US (HQ)
750 Lexington Ave., 20th Floor
Boston, US
One Marina Park Drive, 12th Floor

Keryx Biopharmaceuticals Data and Metrics

Keryx Biopharmaceuticals Financial Metrics

Keryx Biopharmaceuticals's revenue was reported to be $32 m in FY, 2016 which is a 134% increase from the previous period.
USD

Revenue (FY, 2016)

32 m

Revenue growth (FY, 2015 - FY, 2016), %

134%

Gross profit (FY, 2016)

(5.8 m)

Gross profit margin (FY, 2016), %

(18%)

Net income (FY, 2016)

(161.1 m)

EBIT (FY, 2016)

(122.8 m)

Market capitalization (19-Jul-2017)

777.7 m

Closing share price (19-Jul-2017)

7.7

Cash (31-Dec-2016)

111.8 m
Keryx Biopharmaceuticals's current market capitalization is $777.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

7 m10.8 m13.7 m32 m

Revenue growth, %

55%26%134%

Cost of goods sold

37.8 m

Gross profit

(5.8 m)

Gross profit Margin, %

(18%)

R&D expense

29.5 m

General and administrative expense

84.6 m

Operating expense total

54.1 m122.1 m124.7 m154.7 m

EBIT

(47.1 m)(111.2 m)(111.1 m)(122.8 m)

EBIT margin, %

(673%)(1028%)(812%)(384%)

Interest income

351 k411 k(12 m)(38.3 m)

Pre tax profit

(46.7 m)(110.8 m)(123.1 m)(161 m)

Income tax expense

700 k90 k80 k

Net Income

(46.7 m)(111.5 m)(123.1 m)(161.1 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

55.7 m74.3 m200.3 m111.8 m

Accounts Receivable

834 k3.7 m5.2 m

Inventories

7.8 m41.9 m12.7 m

Current Assets

56.9 m98.6 m249.3 m132.9 m

PP&E

349 k1.5 m5.1 m4.2 m

Goodwill

3.2 m3.2 m3.2 m3.2 m

Total Assets

60.8 m103.6 m258.7 m141.4 m

Accounts Payable

14 m24.1 m21.3 m21.2 m

Current Liabilities

15.3 m29.3 m77.6 m21.6 m

Total Liabilities

149.7 m

Additional Paid-in Capital

485 m624.6 m761.2 m827.1 m

Retained Earnings

(439.3 m)(550.9 m)(674 m)(835.1 m)

Total Equity

45.4 m73.5 m86.9 m(8.3 m)

Financial Leverage

1.3 x1.4 x3 x-17 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(46.7 m)(111.5 m)(123.1 m)(161.1 m)

Depreciation and Amortization

54 k306 k596 k1 m

Accounts Receivable

(834 k)(2.8 m)(1.6 m)

Inventories

(7.8 m)(29.2 m)(2.3 m)

Accounts Payable

6.8 m10.1 m(9.2 m)88 k

Cash From Operating Activities

(34.3 m)(81 m)(127.5 m)(86.6 m)

Purchases of PP&E

(346 k)(1.5 m)(2.8 m)(2.1 m)

Cash From Investing Activities

(346 k)(13 m)8.7 m(2.1 m)

Cash From Financing Activities

75.7 m112.6 m244.7 m198 k
Y, 2016

Financial Leverage

-17 x

Keryx Biopharmaceuticals Market Value History

Keryx Biopharmaceuticals Online and Social Media Presence

Keryx Biopharmaceuticals Company Life and Culture

You may also be interested in